ALK-Abello shares rise following 4Q earnings report

Published 19/02/2025, 11:38
© Reuters.

Investing.com -- Shares of ALK-Abello A/S (CPH:ALK-B) climbed 2.5% as the company’s fourth-quarter sales came close to consensus estimates, despite a slight miss in gross profit.

The company’s earnings report indicated that fourth-quarter sales were only 1% shy of company consensus, with tablet sales exceeding expectations by 3%, which helped offset weaker performance in subcutaneous immunotherapy (SCIT)/sublingual immunotherapy (SLIT)-drops and other products.

The earnings before interest and taxes (EBIT) for the fourth quarter fell 22% behind consensus, mainly due to lower gross margin and higher sales, marketing, and administrative expenses. These total costs included one-off expenses related to European optimization initiatives and revisions to the company’s strategy in China.

Excluding these one-time costs, the capacity cost to revenue ratio was 48%, suggesting an adjusted EBIT of DKK240-245 million, which would be just 6%-8% behind consensus.

Looking ahead, ALK-Abello presented its revenue growth target for 2025, projecting a 9%-13% increase at constant exchange rates (CER), with consensus estimates hovering around the midpoint of this range. The company also reaffirmed its EBIT margin outlook at approximately 25%, aligning with broad consensus estimates.

The anticipated growth is expected to be driven primarily by double-digit percentage increases in tablet sales across all regions, attributed mainly to volume growth with a reduced impact from pricing and rebate adjustments compared to what was observed in 2024. Furthermore, the company expects a slight increase in gross margin.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.